Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven squamous cell skin carcinoma~* Recipient of a renal organ transplant at least one year prior to study enrollment~* Receiving a CNI for at least 6 months prior to diagnosis of skin cancer~* No current evidence of graft rejection, except low-grade, chronic graft rejection~* Measurable disease by caliper measurement~* Life expectancy \> 6 months~* Age of at least 18 years~* Adequate organ and marrow function as determined by ANC, HGB, PLT, Total Bili, AST, and creatinine clearance~* Ability to understand/willingness to sign a written informed consent form~Exclusion Criteria:~* Inability to give informed consent~* Major surgery within 4 week prior to starting study drug~* Chronic or non-healing open wounds~* Pregnant and nursing women~* Women and men of child-bearing potential must agree to use adequate contraception prior to study entry and for the study duration~* Prior use of an mTOR inhibitor~* Pre-existing clinically significant cardiac, hepatic, pulmonary, or renal dysfunction~* HIV-positive patients~* Proteinuria (\> 1 gram)~* Prior or current history of uncontrolled hyperlipidemia (cholesterol \> 302 mg/dl or triglycerides 354 mg/dl~* Currently receiving any investigational agents~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sirolimus (mTOR inhibitors)~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus treatment (Type: EXPERIMENTAL): Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).